Press release Biocartis Group NV: SeptiCyte® RAPID Receives 510(k) clearance by US FDA
30 nov. 2021 11h40 HE
|
Biocartis NV
PRESS RELEASE: 30 November 2021, 17:40 CET SeptiCyte® RAPID Receives 510(k) clearance by US FDA Mechelen, Belgium, 30 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an...
Olaparib Reduces Organ Damage in Sepsis
13 sept. 2021 10h00 HE
|
Experimental Biology and Medicine
WASHINGTON, Sept. 13, 2021 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 246, Issue 17, September, 2021) examines the role of olaparib in sepsis. The...
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
29 juin 2021 13h58 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Jafron Biomedical Announces Global Advisory Board
21 juin 2021 07h00 HE
|
Jafron Biomedical Co.,Ltd.
ZHUHAI, China, June 21, 2021 (GLOBE NEWSWIRE) -- Jafron Biomedical, a pioneer in the blood purification industry, announced it's founding the Global Advisory Board, which includes the world’s top...
HelixBind Awarded $3MM NIH Grant to Support Testing of Its RaPID Diagnostic Platform for Invasive Infections Associated with Sepsis
17 juin 2021 08h30 HE
|
HelixBind
BOXBOROUGH, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
Global Bloodstream Infection Testing Market to Garner a Revenue of $7,722.2 Million, Growing at a CAGR of 8.4% during 2019-2027 - [247 Pages] Absolute Report by Research Dive
24 mars 2021 09h45 HE
|
Research Dive
New York, USA, March 24, 2021 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global bloodstream infection testing market is forecasted to garner a revenue of $7,722.2...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
03 sept. 2020 21h42 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test
24 août 2020 11h47 HE
|
HelixBind
BOXBOROUGH, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
HelixBind Awarded $3MM Grant from NIH and Expands Clinical Advisory Board to Accelerate Development of Its Diagnostic Platform for Invasive Infections
10 juin 2020 10h29 HE
|
HelixBind
BOXBOROUGH, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies
04 mars 2020 09h56 HE
|
Arch Biopartners
TORONTO, March 04, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it is expanding the dose range of Metablok...